Prostate cancer not likely to be cause of death in men with low-risk disease

the ONA take:

Relatively unaggressive prostate tumors are not likely to develop into metastatic disease or result in death, according to a study by researchers at the Brady Urological Institute at Johns Hopkins.

The researchers analyzed survival data of 1,298 men enrolled over the past 20 years in an active surveillance program Johns Hopkins. Of the participants, just two men died of prostate cancer, and three developed metastatic disease.

Urologists carefully selected which men were candidates for active surveillance and monitored the participants. Selection was based, in part, on Gleason scores determined by pathologic evaluation of prostate biopsy tissue.

In 1995, when the study began, the men underwent annual biopsy until age 75 years. Annual biopsies are no longer required among those men in the lowest risk group; however, when a biopsy is performed, MRI-guided technology is used and pathologists are asked to check biopsy tissue levels of proteins made by the PTEN gene, a biomarker for prostate cancer aggressiveness.

A benefit of using active surveillance for men who prostate cancer is very low or low-risk is reduction in rates of complications and costs of prostate cancer treatments.

Prostate cancer is not likely to be cause of death in men with low-risk disease
Relatively unaggressive prostate tumors are not likely to develop into metastatic disease or result in death.
Men with relatively unaggressive prostate tumors and whose disease is carefully monitored by urologists are unlikely to develop metastatic prostate cancer or die of their cancers, according to results of a study by researchers at the Brady Urological Institute at Johns Hopkins, who analyzed survival statistics up to 15 years.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs